Johnson & Johnson
JNJ
Company Profile
Business description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Contact
One Johnson & Johnson Plaza
New BrunswickNJ08933
USAT: +1 732 524-0400
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
140,800
Johnson & Johnson News & Analysis
markets
US stock market outlook: Where to find value after April’s rally
Our reallocation strategy is working as intended. Opportunities remain in AI, tech, and small-caps.
personal-finance
Howard Marks warns of stock market froth
The renowned investor has penned his first investor letter for 2025 and it’s a ripper. He runs through what bubbles are, which ones he’s experienced, and whether today’s markets qualify as the third major bubble of this century.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.40 | 71.60 | -0.80% |
| CAC 40 | 8,325.66 | 78.33 | -0.93% |
| DAX 40 | 24,896.53 | 99.28 | -0.40% |
| Dow JONES (US) | 52,319.20 | 136.46 | 0.26% |
| FTSE 100 | 10,445.04 | 52.08 | -0.50% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,213.72 | 393.58 | 1.52% |
| Nikkei 225 | 70,474.96 | 412.64 | 0.59% |
| NZX 50 Index | 13,610.50 | 11.16 | -0.08% |
| S&P 500 | 7,499.36 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,722.90 | 71.70 | -0.82% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |